+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are studying patients with breast cancer who have limited nodal disease confirmed by biopsy and are undergoing primary surgery. The study evaluates targeted sentinel node biopsy TSNB as a method to assess axillary lymph node involvement and compares its outcomes to other staging methods. This observational audit aims to collect data on surgical results, arm lymphoedema, and disease progression, benchmarking against previous trials and current guidelines. Participants will undergo TSNB where the marked, biopsy-proven positive node is removed along with sentinel nodes, following standard local practices and protocols such as those used in the ATNEC trial. The marked node may be identified using clips, dyes, magnetic seeds, or other techniques. At least three nodes should be removed for adequate assessment. Further axillary treatment decisions after TSNB will be made by the treating multidisciplinary team based on local protocols. During the study, participants will be followed for up to 60 months with regular assessments of nodal metastases, identification rates of marked nodes, false negative rates, and arm lymphoedema. Secondary outcomes include axillary, regional, and local recurrence, disease-free survival, and overall survival. Data collection will include histology results and clinical follow-up to monitor outcomes and treatment effectiveness in this patient population.

Age: 18Years +All Genders
14 locations
E

Actively Recruiting

Researchers are evaluating the long-term effects of lidocaine infusions given during and after surgery to reduce moderate or severe chronic post-surgical pain in adult women undergoing elective breast cancer surgery. This large, international, randomized, double-blind trial aims to detect a meaningful reduction in chronic pain one year after surgery and also assesses safety, pain relief, opioid use, nerve-related pain symptoms, psychological health, and quality of life. Participants receive either a lidocaine infusion starting with an intravenous bolus after anesthesia induction, continuing with an intraoperative intravenous infusion, and followed by a post-operative subcutaneous infusion for up to 24 hours. The lidocaine dosing is adjusted by lean body weight with a cap, while the comparison group receives a saline placebo infusion following the same schedule. Day-case surgeries receive only the intraoperative treatments without the post-operative infusion. During the trial, participants will be monitored for pain severity, opioid consumption, nerve-related symptoms, psychological distress, physical functioning, quality of life, safety events, and health care costs up to one year after surgery. The primary outcome is the incidence of moderate or severe chronic post-surgical pain reported at one year. Assessments include patient-reported outcomes, pain scores at 24 hours postoperatively, and opioid use at various timepoints. The total participation duration extends up to one year after surgery.

Age: 18Years +FEMALEPhase 3
49 locations
P

Actively Recruiting

The trial investigates the role of ixazomib in patients with relapsed multiple myeloma who have previously undergone autologous stem cell transplant ASCT. It is a phase III, randomized, controlled, multi-center, open-label study aiming to assess whether adding a proteasome inhibitor to salvage ASCT conditioning improves depth of response and how consolidation and maintenance therapy influence the durability of response. The study also evaluates overall survival, progression-free survival, response rates, minimal residual disease, toxicity, and quality of life. Participants first receive re-induction therapy with 4 to 6 cycles of ixazomib, thalidomide, and dexamethasone ITD, each cycle lasting 28 days. Those achieving at least stable disease are randomly assigned to receive either conventional ASCT using melphalan alone or augmented ASCT combining melphalan with ixazomib. After ASCT, participants with minimal response or better are further randomized to either receive consolidation with 2 cycles of ITD followed by ixazomib maintenance until disease progression or no further treatment. During the study, participants undergo regular assessments including response evaluation 100 days post-ASCT, monitoring of progression-free survival for up to 120 months, and measurement of minimal residual disease at several time points. Safety and toxicity are closely monitored throughout re-induction, post-ASCT, consolidation, and maintenance phases. Quality of life questionnaires are completed at baseline, post-re-induction, post-ASCT, and during follow-up visits up to 24 months. The study plans to register 406 participants, with 284 randomized at the first stage and 248 at the second stage.

Age: 18Years +All GendersPhase 3
91 locations